Talbird SE, Mauskopf J, Smets E, Brogan AJ. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010 Dec 23;28(Suppl 1):129-46.
Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine. 2010 Nov 19;28(Suppl 6):G14-22.
Talbird SE, Taylor TN, Knoll S, Frostad CR, Marti SG. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010 Nov 19;28(Suppl 6):G23-9.
Talbird SE, Ismaila AS, Taylor TN. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine. 2010 Nov 19;28(Suppl 6):G3-G13.
Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine. 2010 Nov 19;28(Suppl 6):G30-8.
Knoll S, Jochum D, Talbird S. Comparative cost benefit analysis of two new Pneumococcal Conjugate Vaccines (PHiD-CV and PCV-13). Klin Padiatr. 2010 Jun 1;222(Suppl 1):S51-2.
Talbird SE, Bell K, Graham JB, Deal L, Mauskopf J. Cost-effectiveness analysis for treatment of symptomatic uterine fibroids among premenopausal women seeking to retain uterus. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A183.
Bapat B, Davis KL, Bell K, Deal L, Talbird SE. Treatment patterns and economic burden of uterine fibroids in a United States managed care database. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 25, 2010. [abstract] Value Health. 2010 May; 13(3):A182.